GENENTECH PULMOZYME SALES ARE $111.3 MIL. IN 1995, MARKET PENETRATION AT 60%, COMPANY REPORTS; PFIZER NORVASC 4TH QUARTER SALES GROWTH IS 73%
Genentech's cystic fibrosis therapy Pulmozyme (dornase alfa) is being used by 60% of CF patients over the age of five, Genentech CEO Arthur Levinson, PhD, told the Hambrecht & Quist health care conference Jan. 10 in San Francisco.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth